PrEP “on demand”: A promising approach

September 8, 2016

Pre-exposure prophylaxis (PrEP) continues to demonstrate its effectiveness and each new study shows that it considerably reduces the risk of HIV transmission. The Truvada medication, which prevents the virus from multiplying, was, moreover, approved by Health Canada as a preventive treatment. A Canadian study confirmed that, when taken continuously, it has a 98% rate of success in preventing infection of persons newly exposed to the risk of transmission.

PrEP “on demand”, a one-off prophylactic treatment prescribed during bouts of high risk of exposure to transmission, occupied a place of prominence in the debates at the Durban conference. A first study had established its effectiveness at 86%. A new French study, conducted from November 2014 to 2016 with 362 individuals, yielded results that were even more spectacular. Only one person – who, in fact, had interrupted the PrEP – was infected.

When well managed, PrEP “on demand” represents a promising approach for populations that are highly vulnerable to the risk of HIV transmission, have very high prevalence rates, and among whom the transmission chain seems difficult to break. Not only does it have fewer secondary effects than the continuous treatment formula, but it, moreover, leads to substantial savings which could encourage its development among the biggest pools of high-risk populations

Share on FacebookEmail this to someoneTweet about this on Twitter